Retlirafusp alfa
- Generic Name
- Retlirafusp alfa
- Drug Type
- Biotech
- CAS Number
- 2395839-91-3
- Unique Ingredient Identifier
- JP6N6TA92L
A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT04624217
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Drug: SHR-1701+Paclitaxel+carboplatin
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT04580498
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2020-09-23
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 15
- Registration Number
- NCT04560244
Phase â… /â…¡ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04407741
- Locations
- 🇨🇳
Department of Biotherapeutic, Chinese PLA General Hospital, Beijing, China
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
- Conditions
- Breast CancerMetastatic Cancer
- Interventions
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 319
- Registration Number
- NCT04355858
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Trial of SHR-1701 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Atridia Pty Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT04324814
- Locations
- 🇦🇺
Linear Clinical Research, Perth, Western Australia, Australia
🇦🇺Icon Cancer Care Centre, South Brisbane, New South Wales, Australia
🇦🇺Scientia Clinical research, Sydney, New South Wales, Australia
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT04282070
- Locations
- 🇨🇳
Cancer Hospital of Guangzhou Sun Yat-sen University, Guangzhou, Guangdong, China
SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 193
- Registration Number
- NCT03774979
- Locations
- 🇨🇳
Anhui Chest Hospital-Departmen of Tumor Radiotherapy, Hefei, Anhui, China
🇨🇳Hunan Cancer Hospital-Gynecologic Oncology, Changsha, Hunan, China
🇨🇳Xinxiang Central Hospital-Department of Respiratory Physicians, Xinxiang, Henan, China
SHR-1701 in Metastatic or Locally Advanced Solid Tumors
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 206
- Registration Number
- NCT03710265
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.